Claims
- 1. A pharmaceutical composition for the treatment of conditions mediated through histamine H.sub.2 -receptors, comprising an effective amount for the treatment of the said condition of a compound of formula (I) ##STR6## or a physiologically acceptable salt or hydrate thereof in which R.sub.1 and R.sub.2 each represent methyl groups or together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino or hexamethylenimino group;
- R.sub.3 represents hydrogen or methyl;
- Alk represents a straight or branched alkylene chain of 1 to 6 carbon atoms;
- R.sub.4 represents a hydrogen atom and R.sub.5 represents a C.sub.1-4 alkyl group; or R.sub.4 and R.sub.5 together with the atoms to which they are attached form a tetrahydropyranyl ring; and
- either n is zero, X is oxygen, m is 3 or 4, and Q is a benzene ring linked through the 1- and 3-positions;
- or n is 1, X is sulphur, m is 2, and Q is a furan ring linked through the 2- and 5-positions with optionally a methyl substituent on the carbon atom adjacent to the group R.sub.1 R.sub.2 NCH.sub.2, or Q is a thiophene ring linked through the 2- and 4-positions with the group R.sub.1 R.sub.2 NCH.sub.2 in the 2-position;
- with the proviso that when Q is other than a benzene ring R.sub.1 and R.sub.2 are methyl groups, together with at least one pharmaceutically acceptable carrier or diluent.
- 2. A pharmaceutical composition for the treatment of conditions mediated through histamine H.sub.2 -receptors, comprising an effective amount for the treatment of the said condition of a compound of formula (II) ##STR7## or a physiologically acceptable salt or hydrate thereof, in which R.sub.1 R.sub.2 N is a pyrrolidino, piperidino or hexamethylenimino ring; m is 3 or 4; R.sub.3 represents hydrogen or methyl; Alk represents a straight or branched alkylene chain of 1 to 6 carbon atoms; and R.sub.4 represents a hydrogen atom and R.sub.5 represents a C.sub.1-4 alkyl group; or R.sub.4 and R.sub.5 together with the atoms to which they are attached form a tetrahydropyranyl ring.
- 3. A pharmaceutical composition according to claim 2 in which, in formula (II), R.sub.1 R.sub.2 N is a piper idino ring, m is 3 and R.sub.3 is methyl.
- 4. A pharmaceutical composition according to claim 1 in which, in formula (I); Alk represents methylene or ethylene and R.sub.4 and R.sub.5 together with the atoms to which they are attached form a tetrahydropyranyl ring or R.sub.4 represents hydrogen and R.sub.5 represents methyl or ethyl.
- 5. A pharmaceutical composition for the treatment of conditions mediated through histamine H.sub.2 -receptors comprising an effective amount of a compound selected from
- 1-methyl-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-3-[(tetrahydro-2-pyranyl)oxymethyl]-1H-1,2,4-triazole-5-amine;
- 3-[(ethoxymethoxy)methyl]-1-methyl-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-1H-1,2,4-triazole-5-amine;
- and physiologically acceptable salts thereof, together with at least one pharmaceutically acceptable carrier or diluent.
- 6. A pharmaceutical composition according to claim 1 in a form adapted for oral administration.
- 7. A compound of the formula (II) ##STR8## or a physiologically acceptable salt or hydrate therof in which R.sub.1 R.sub.2 N is a pyrrolidino, piperidino or hexamethylenimino ring; m is 3 or 4; R.sub.3 represents hydrogen or methyl; Alk represents a straight or branched alkylene chain of 1 to 6 carbon atoms; and R.sub.4 represents a hydrogen atom and R.sub.5 represents a C.sub.1-4 alkyl group; or R.sub.4 and R.sub.5 together with the atoms to which they are attached form a tetrahydropyranyl ring.
- 8. A compound according to claim 7 in which R.sub.1 R.sub.2 N is a piperidino ring, m is 3 and R.sub.3 is methyl.
- 9. A compound according to claim 7 in which Alk represents methylene or ethylene and R.sub.4 and R.sub.5 together with the atoms to which they are attached form a tetrahydropyranyl ring or R.sub.4 represents hydrogen and R.sub.5 represents methyl or ethyl.
- 10. 1-Methyl-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-3-[(tetrahydro 2-pyranyl)oxymethyl]-1H-1,2,4-triazole-5-amine; or
- 3-[(ethoxymethoxy)methyl]-1-methyl-N-[3-[3-(1-piperidinylmethyl)phenoxy]propyl]-1H-1,2,4-triazole-5-amine; or a physiologically acceptable salt thereof.
- 11. A method for the treatment of a condition mediated through histamine H.sub.2 -receptors which comprises administering to a patient an effective amount to alleviate said condition of a compound of formula (I) as defined in claim 1.
- 12. A method for the treatment of a condition mediated through histamine H.sub.2 -receptors which comprises administering to a patient an effective amount to alleviate said condition of a compound as claimed in claim 7.
Priority Claims (1)
Number |
Date |
Country |
Kind |
8122607 |
Jul 1981 |
GBX |
|
Parent Case Info
This application is a continuation of application Ser. No. 401,152 now abandoned, filed July 22, 1982.
Foreign Referenced Citations (1)
Number |
Date |
Country |
2063253 |
Jun 1981 |
GBX |
Continuations (1)
|
Number |
Date |
Country |
Parent |
401152 |
Jul 1982 |
|